Evidence map›Paper›PMID 42855523›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2026

Age-stratified efficacy and safety of esaxerenone versus angiotensin II receptor blockers in older patients with hypertension: a predefined subanalysis of the ESCORT-HT study.

Kazuomi Kario, Hiroyuki Ohbayashi, Hajime Ishii, Mitsutoshi Kato, Minoru Nozaki, Norio Abiru, Toshiki Fukui, Kazushi Nomura, Yasushi Fukushima, Naoki Itabashi and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Kazuomi KarioDivision of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan. kkario@jichi.ac.jp.
Hiroyuki OhbayashiTohno Chuo Clinic, Mizunami, Gifu, Japan.
Hajime IshiiKashinoki Clinic, Date, Fukushima, Japan.
Mitsutoshi KatoKato Clinic of Internal Medicine, Katsushika-ku, Tokyo, Japan.
Minoru NozakiMedical Corporation Shirayurikai Swing Nozaki Clinic, Musashino, Tokyo, Japan.
Norio AbiruMidori Clinic, Nagasaki-city, Nagasaki, Japan.
Toshiki FukuiOlive Takamatsu Medical Clinic, Takamatsu, Kagawa, Japan.
Kazushi NomuraNomura Clinic, Itabashi-ku, Tokyo, Japan.
Yasushi FukushimaFukuwa Clinic, Chuo-ku, Tokyo, Japan.
Naoki ItabashiItabashi Diabetes and Dermatology Medical Clinic, Koga, Ibaraki, Japan.
Kazuaki UchiyamaUchiyama Clinic, Joetsu, Niigata, Japan.
Masafumi NishizawaMinamisanriku Hospital, Motoyoshi, Miyagi, Japan.
Yoshiki HataMinamino Cardiovascular Hospital, Hachioji, Tokyo, Japan.
Noriko NakamuraPrimula Clinic, Kagoshima-city, Kagoshima, Japan.
Satoshi KodonoFukuhama Chuo Clinic, Fukuoka-city, Fukuoka, Japan.
Kunio HiranoHirano Clinic, Morioka, Iwate, Japan.
Tomohiro KatsuyaKatsuya Clinic, Amagasaki, Hyogo, Japan.
Tatsuo ShimosawaDepartment of Clinical Laboratory, School of Medicine, International University of Health and Welfare, Narita, Chiba, Japan.
Mitsuru OhishiDepartment of Cardiovascular Medicine and Hypertension, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima-city, Kagoshima, Japan.
Kazuhito ShiosakaiData Intelligence Department, Daiichi Sankyo Co. Ltd., Shinagawa-ku, Tokyo, Japan.
Taketoshi FurugoriMedical Affairs Planning Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd., Chuo-ku, Tokyo, Japan.
Takashi TaguchiMedical Evidence Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd., Chuo-ku, Tokyo, Japan.
ESCORT-HT investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ESCORT-HT study recently demonstrated non-inferiority of esaxerenone to angiotensin II receptor blockers (ARBs) in lowering morning home systolic blood pressure (SBP) in Japanese patients aged ≥65 years with inadequately controlled hypertension on amlodipine. This predefined subgroup analysis of the ESCORT-HT study analyzed age-related differences in the efficacy and safety of esaxerenone relative to ARBs. In the 65-74-year subgroup, 98 patients were treated with esaxerenone and 94 with an ARB; in the ≥75-year subgroup, 104 were treated with esaxerenone and 106 with an ARB. The least squares mean difference in morning home SBP between the two treatment groups at end of treatment was -1.1 (95% confidence interval [CI] -3.8, 1.6) mmHg for the 65-74-year subgroup and -2.2 (95% CI -5.2, 0.9) mmHg for the ≥75-year subgroup. The upper bound of the 95% CI was within the pre-defined non-inferiority margin of <3.8 mmHg. The urine albumin-to-creatinine ratio decreased in all groups at Week 12, regardless of age or treatment, and N-terminal pro-B-type natriuretic peptide levels decreased in esaxerenone-treated patients, regardless of age. The incidence of treatment-emergent adverse events was 34.3% (esaxerenone) and 32.0% (ARB) in patients 65-74 years, and 16.7% and 29.6%, respectively, in patients aged ≥75 years. There were no notable increases in the incidence of hyperkalemia or hypokalemia, relative to ARBs, in any of the age subgroups. This predefined subgroup analysis of the ESCORT-HT study showed antihypertensive effects consistent with the non-inferiority of esaxerenone to ARBs in both age groups, and suggested a potential cardioprotective effect, including for patients aged ≥75 years.

Indexed as

AgeAngiotensin II receptor blockerEsaxerenoneMorning hypertensionSubgroup analysis

Identifiers

PMID42855523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.